Document is current
Any future updates will be listed below
-
Authors
Hsiao, Fu-Jung
Chen, Wei-Ta https://orcid.org/0000-0003-2355-3540
Pan, Li-Ling Hope
Liu, Hung-Yu
Wang, Yen-Feng
Chen, Shih-Pin
Lai, Kuan-Lin
Coppola, Gianluca
Wang, Shuu-Jiun
-
Funding
Funding for this research was provided by:
Ministry of Science and Technology, Taiwan (109-2314-B-075 -050 -MY2, 108-2321-B-010-001, 108-2321-B-010-014-MY2, 110-2321-B-010-005, and 111-2321-B-010-004, 108-2221-E-010-004 and 109-2221-E-003-MY2)
- License Information
-
More Information
Article History
Received: 12 December 2021
Accepted: 20 January 2022
First Online: 5 February 2022
Declarations
:
: Participants provided signed informed consent. The hospital’s institutional review board approved the study protocol (VGHTPE: IRB 2019–07-001B).
: FJ Hsiao, WT Chen, LL Pan, HY Liu, YF Wang, SP Chen and KL Lai declare no potential conflicts of interest. G Coppola reports travel fees from Novartis Italy, Eli Lilly, and TEVA, all outside the submitted work. SJ Wang reports grants and personal fees from Novartis Taiwan, personal fees from Daiichi-Sankyo, grants and personal fees from Eli-Lilly, personal fees from Allergan, personal fees from Pfizer, Taiwan, personal fees from Bayer, Taiwan, outside the submitted work.
